What is Omarigliptin?

Omarigliptin (Omarigliptin) is a potent oral dipeptidyl peptidase-4 (DPP-4) inhibitor with a long plasma half-life and is administered once a week. Ologliptin, available in common strengths of 25 and 12.5 mg, is an oral tablet and is an oral DPP-4 inhibitor approved in Japan for the treatment of adults with type 2 diabetes mellitus (T2DM). Ologliptin caninhibitDPP-4 to increase incretin levels (GLP-1 and GIP), thereby inhibiting glucagon release, which in turn increases insulin secretion, reduces gastric emptying and lowers blood glucose levels.

In a 12-week Phase 2b dose-ranging discovery study of ologliptin, dose-dependent 2-hour postprandial glucose reductions, fasting plasma glucose reductions, glycated hemoglobin (HbA1c) reductions and a safety profile were similar to those of the once-daily DPP-4 inhibitor sitagliptin (sitagliptin). Ologliptin is rapidly absorbed and has significantly high bioavailability. The pharmacokinetics (PK) of ologliptin is biphasic, with a long terminal half-life (>100 hours). For the 25 mg dose administered once weekly, the long terminal period had no significant effect on drug exposure, with minimal accumulation occurring after multiple doses.

The original drug Ologliptin is not marketed in the country and is therefore not included in medical insurance. The price of each box of generic Ologliptin drugs currently on the market overseas may be more than more than 1,000 yuan (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.